

## Template<sup>1</sup> for summarising studies addressing intervention questions

### **Instructions to fill the table:**

- When no element can be added under one or more heading, include the mention:
  - “Not applicable” when an item is not to be informed (according to the type of study);
  - “Not described” when an item must be informed but no information is given in the publication.
- Describe all the results given in the manuscript even if those are not relevant to the study aim.
- Refer to the addendum for added results calculated or reconstructed by the reviewer.

Name of Person completing template:

Date of completion:

HEADINGS	DESCRIPTION
<b>Bibliographic citation</b>	Use Vancouver style (Authors <sup>2</sup> . Title. Journal name. Publication Date; Volume (Issue):Page (Numbers)  Insert the link to the publication.
<b>Sources of funding and competing interest</b>	Report: <ul style="list-style-type: none"> <li>➤ The source of funding cited in the paper: give name(s) of organisation or corporation. Specify if possible the source type (public research funds, NGO, government, Academic/university healthcare industry or other)</li> <li>➤ Competing interests: Write “Stated” or “Not Stated” and specify if any</li> </ul>
<b>Setting</b>	Number of centres, countries involved, healthcare setting, urban/rural/mixed
METHOD	
<b>Study design (cited by author or actual)</b>	Specify the study design: Prospective study, randomized study, cross sectional study, retrospective study, cohort study, case control study, time series, before and after studies, other. Precise if it's the design cited by author(s).
<b>Eligibility criteria</b>	State the inclusion and exclusion criteria cited in the paper.
<b>Interventions</b>	Precise details of the interventions for each group (including dose, length, regimen and timing when relevant)
<b>Primary outcome measure</b>	State primary outcome measure identified by author(s), usually the one used for sample size calculation
<b>Secondary outcome measure(s)</b>	State secondary outcome measures identified by the author(s)

<sup>1</sup> Minimum data abstracted from a single study to allow consistent comparison across studies and to inform a group process in evidence synthesis.

<sup>2</sup> Limit to the first 6 authors and then add *et al.* If there is a society, it counts as an author.

HEADINGS	DESCRIPTION
<b>Sample size</b>	Give the number of patients needed (= the calculated before protocol) as cited (described) by the author(s) (should clearly report if it is numbers by group or not)
<b>Randomisation method</b>	Describe the randomisation method and the blinding method, if relevant (as cited by authors)
<b>RESULTS</b>	
<b>Numbers</b>	Give the number of patients involved in each group as described by the author(s), Give the number of patients analysed by group as described by the author(s), in particular in the intention to treat analysis in comparative studies
<b>Study duration</b>	Start and end dates of the study (precise if includes follow up or not), precise inclusion and follow up periods (length rather than dates)
<b>Patients characteristics and group comparability</b>	Describe baseline characteristics cited in the paper (precise if it is on involved and/or analysed numbers) Highlight discrepancies between groups (i.e. involved and analysed)
<b>Effect size – primary outcome</b>	Summary of the primary outcome in each and between groups: effect size and its precision (mean or percentage, p value, CI: If one or another not reported precise that it is not cited)
<b>Effect size – Secondary outcome(s)</b>	Summary of the secondary outcome(s) in each and between groups: effect size and its precision (mean or percentage, p value, CI: If one or another not reported precise that it is not cited)
<b>Harms (adverse events)</b>	Define and describe observed harms per groups as reported in the paper. Precise mean(s) or percentage(s) and p value(s), if available.
<b>CRITICAL APPRAISAL OF THE STUDY QUALITY</b>	
<b>Authors conclusion</b>	Report the authors' conclusion
<b>Results validity</b>	Detailed comments on: <ul style="list-style-type: none"> <li>➤ External validity: setting, inclusion/exclusion criteria, interventions, etc.</li> <li>➤ Internal validity: sample size (alpha and beta used for calculation), randomisation and blinding, use of inappropriate statistical analysis, group comparability at baseline, etc.</li> </ul> General comments (including own conclusion of the reviewer if possible)
<b>Other /Addendum</b> <b>Optional</b>	Further calculations made by the reviewer (NNT, RR, OR, CI, ..)

The evidence table working group would appreciate to hear about any comments, questions; you may have on this template. Please send your feedback to the G-I-N Office: [office@g-i-n.net](mailto:office@g-i-n.net)

Special thanks for the development of this template are addressed to:

- Najoua Mlika-Cabanne (HAS, FR), Joint speaker
- Sara Twaddle (SIGN, UK)
- Michel Laurence (HAS, FR)
- Hans de Beer (CBO, NL)
- Robin Harbour (SIGN, UK)